In the long struggle to find footholds against cancers that have resisted medicine's best efforts, researchers at Mount Sinai and UC San Diego have identified a molecular vulnerability in myelodysplastic syndrome — a rare blood cancer that has offered patients little hope. By tracing how specific mutations warp the RNA splicing process and produce an aberrant protein, the team discovered that existing FDA-approved drugs, MEK inhibitors, may be turned against a disease that has long lacked effective treatment. The finding reminds us that progress in medicine often arrives not through entirely n
Researchers identify MEK inhibitors as potential treatment for myelodysplastic syndrome
Myelodysplastic syndrome is a rare blood cancer with poor prognosis and no effective treatments, affecting patients with limited therapeutic options.
A disease that offered little hope now has a concrete target.
Mark
So they found that a specific gene mutation in blood cancer cells can be targeted with drugs that already exist. That's the core of it?
Mimi
Exactly. The mutations disrupt RNA splicing in a way that creates an altered protein—GNAS—and that altered protein becomes a dependency. MEK inhibitors can exploit that dependency.
Luke
But these are cell models and patient cells in a lab setting, right? We don't yet know if this works in living patients.
Mimi
That's correct. The lab work is solid—they showed sensitivity in both engineered cells and actual patient samples. But clinical trials are just starting.
Mark
Why does it matter that these drugs are already FDA-approved?
Mimi
It accelerates everything. You don't have to develop a new drug from scratch. You can move faster to testing in patients, and the safety profile is already known.
Luke
How many patients have MDS with these specific mutations? The story doesn't say.
Mimi
It doesn't. That's a real gap. We know MDS is rare, but we don't know what fraction of MDS patients carry these particular mutations.
Mark
And the solid tumors mentioned—how confident are we that this will work there too?
Mimi
The mutations do appear in other cancers, so there's biological plausibility. But that's speculative until trials are done.
Luke
So the headline is accurate but the scope is still uncertain. We have a mechanism, a drug target, and early evidence. We don't have clinical proof yet.
Mimi
Right. This is a real advance, but it's early-stage. The trials will tell us whether it translates to actual patient benefit.
O Pulso
- Myelodysplastic syndrome has long been a near-hopeless diagnosis, with patients facing a poor prognosis and almost no effective therapeutic options.
- Mutations in the GNAS gene quietly hijack RNA splicing, forcing cells to produce an abnormal protein that drives cancer growth through a specific, exploitable signaling pathway.
- Researchers engineered stem cell disease models to mirror patient mutations, then used advanced molecular analysis to pinpoint exactly which proteins were steering the disease.
- When both lab-engineered and actual patient cells were exposed to MEK inhibitors — drugs already approved for other cancers — the MDS cells proved strikingly vulnerable.
- Clinical trials are now being launched, and because the same GNAS mutations appear in solid tumors and other blood cancers, the implications of this discovery reach well beyond MDS alone.
In the long struggle to find footholds against cancers that have resisted medicine's best efforts, researchers at Mount Sinai and UC San Diego have identified a molecular vulnerability in myelodysplastic syndrome — a rare blood cancer that has offered patients little hope. By tracing how specific mutations warp the RNA splicing process and produce an aberrant protein, the team discovered that existing FDA-approved drugs, MEK inhibitors, may be turned against a disease that has long lacked effective treatment. The finding reminds us that progress in medicine often arrives not through entirely new weapons, but through the patient work of learning where old ones can be aimed.
A research collaboration between Mount Sinai and UC San Diego has uncovered a concrete therapeutic target in myelodysplastic syndrome, a rare blood cancer that has resisted effective treatment for decades. The discovery, published in Cancer Discovery, centers on mutations that disrupt RNA splicing — the cellular process that governs which proteins are produced — and in doing so, create a vulnerability that existing drugs can exploit.
The mutations occur in a gene called GNAS. When altered, it generates an abnormal protein that forces cancer cells into a dependency on a specific signaling pathway. That pathway can be blocked by MEK inhibitors, a class of drugs already approved by the FDA for other malignancies. The logic is elegant: identify what a cancer cell cannot survive without, then use a tool already on the shelf.
To validate the finding, the team built stem cell models engineered to carry the same mutations found in MDS patients, converting them into the blood cell precursors most relevant to the disease. Advanced RNA analysis revealed how the mutations rewired the cells' molecular machinery. When both the engineered models and real patient cells were exposed to MEK inhibitors, the cancer cells responded with sensitivity to treatment.
Co-senior author Eirini Papapetrou of Mount Sinai's Tisch Cancer Institute noted that this is the first demonstration that the altered GNAS protein accumulates specifically in MDS cells carrying these mutations — and that this accumulation is the disease's exploitable weakness. Collaborator Gene Yeo of UC San Diego described the work as a convergence of disease modeling and molecular analysis toward a genuinely new target.
The reach of the finding may extend further still. The same GNAS mutations appear in other blood cancers and solid tumors, raising the possibility that MEK inhibitors could prove useful across a wider range of malignancies. Clinical trials are now underway, offering patients with myelodysplastic syndrome a path toward treatment options that, until now, simply did not exist.
A team of researchers at Mount Sinai and UC San Diego has identified a potential pathway to treat myelodysplastic syndrome, a rare blood cancer that has long resisted effective therapy. The discovery centers on how certain mutations disrupt RNA splicing—a fundamental cellular process that determines which proteins get made—and in doing so, create vulnerability to drugs already in use against other cancers.
Myelodysplastic syndrome, or MDS, is a blood disorder with a grim clinical picture. Patients face few treatment options and a poor prognosis. The disease arises when bone marrow cells begin to malfunction, producing abnormal blood cells that crowd out healthy ones. For decades, oncologists have lacked effective interventions. This new research, published in Cancer Discovery, offers a concrete target where none existed before.
The researchers traced the problem to mutations in a gene called GNAS. When these mutations occur, they produce an altered version of the GNAS protein. The team discovered that this abnormal protein activates cellular processes that make cancer cells dependent on a particular signaling pathway—one that can be shut down by MEK inhibitors, a class of drugs already approved by the Food and Drug Administration for treating other malignancies. The insight is straightforward but significant: if you can identify what makes a cancer cell vulnerable, you can use existing weapons against it.
To reach this conclusion, the researchers built disease models using stem cells, engineering them to carry the same mutations found in MDS patients. They then converted these cells into hematopoietic progenitor cells, the cell type most relevant to blood cancers. Using advanced RNA analysis techniques, they mapped how the mutations altered the cell's molecular machinery and identified which proteins were driving the disease. When they exposed both their engineered cells and actual patient cells carrying these mutations to MEK inhibitors, the cancer cells proved sensitive to the treatment.
Eirini Papapetrou, an associate professor at Mount Sinai's Tisch Cancer Institute and one of the study's co-senior authors, emphasized the novelty of the finding. This marks the first time researchers have shown that the altered GNAS protein accumulates in MDS cells with these specific mutations, and that this accumulation creates a dependency that MEK inhibitors can exploit. Gene Yeo, her collaborator at UC San Diego, described the work as integrating disease models with cutting-edge molecular analysis to converge on a new therapeutic target.
The implications extend beyond MDS alone. The same GNAS mutations appear in other blood cancers and solid tumors, suggesting that MEK inhibitors might prove useful across a broader range of malignancies. The research team is now moving forward with clinical trials to test whether these drugs can deliver benefit to actual patients. For people living with myelodysplastic syndrome, a disease that has offered little hope, this represents a concrete step toward treatment options that did not exist before.
Citações Notáveis
This is the first study to discover that the altered protein created by GNAS is increased in cells with these mutations in MDS, and this results in the activation of processes that would render the cancer cells vulnerable to the MEK inhibitors.— Eirini Papapetrou, Associate Professor of Oncological Sciences at Mount Sinai's Tisch Cancer Institute
Quer a matéria completa?
Leia o original em Devdiscourse ↗
Health & Medicine